ACCELERATOR PRODUCTION OF CU-64 FOR PET AND RADIOTHERAPY

该项目的目标是开发一种有效的技术， 用小分子生物材料生产高比活度铜-64 加速器铜-64（t1/2 = 12.7小时）是中间半衰期 正电子发射放射性核素已被证明是有用的 正电子发射断层扫描（PET）的放射性示踪剂，以及一个有前途的 用于治疗结肠直肠癌的放射治疗剂。铜-64 目前反应堆生产的，因为这种放射性核素只能是 在少数反应堆设施中生产，其可用性 极其有限。 我们建议开发一种创新的放射性同位素靶和分离 该系统将允许生产临床有用的量 铜-64与传统的PET回旋加速器以及与低 能量线性加速器，最近已成为PET。 铜-64将通过64 Ni（p，n）反应产生。在第一阶段， 将确定最佳目标辐照条件， 将开发用于分离和纯化高特异性的 活性铜-64和用于回收镍-64靶材料。 这些研究将导致设计一个独立的，自动化的 铜-64的加速剂生产和提纯系统 成像和放射治疗所需的量。 拟议的商业应用：铜-64生产系统 在这个项目中开发的将立即用于研究人员， 利用医院的回旋加速器和现有的放射性药物 加速器设施。一个方便的系统的可用性 现场，按需生产铜-64将促进进一步 使用铜标记的放射性核素的成像和放射治疗方案的开发 化合物.

The goal of this project is to develop an efficient technique for the production of high specific activity copper-64 with small biomedical accelerators. Copper-64 (t 1/2 = 12.7 hr.) is an intermediate half-life positron emitting radionuclide which has been shown to be a useful radiotracer for positron emission tomography (PET) as well as a promising radiotherapy agent for the treatment of colorectal cancer. Copper-64 is currently reactor-produced and, because this radionuclide can only be produced at a small number of reactor facilities, its availability is extremely limited. We propose to develop an innovative radioisotope target and separation system which will allow the production of clinically useful quantities of copper-64 with conventional PET cyclotrons as well as with the low energy linear accelerators which have recently become available for PET. Copper-64 will be produced by the 64Ni(p,n) reaction. In Phase I, the optimum target irradiation conditions will be determined, and techniques will be developed for the separation and purification of high specific activity copper-64 and for recovery of the nickel-64 target material. These studies will lead to the design of a self-contained, automated system for the accelerator production and purification of copper-64 in the quantities required for imaging and radiotherapy. PROPOSED COMMERCIAL APPLICATION: The copper-64 production system developed in this program would be of immediate use to researchers having access to hospital-based cyclotrons and to existing radiopharmacy-based accelerator facilities. The availability of a convenient system for the on-site, on-demand production of copper-64 will facilitate the further development of imaging and radiotherapy protocols using copper-labeled compounds.